Production (Stage)
Telomir Pharmaceuticals, Inc.
TELO
$2.07
-$0.03-1.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 65.15% | 68.93% | -246.56% | 6.54% | -1,195.22% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -100.00% | -100.00% | -100.00% | -- |
| Total Other Non-Cash Items | -- | -70.67% | 35,759.70% | -- | -- |
| Change in Net Operating Assets | -152.14% | 336.96% | 111.73% | -105.30% | 90.74% |
| Cash from Operations | 55.50% | 44.28% | 49.96% | -4,432.14% | -163.61% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -108.48% | -72.86% | -- |
| Total Debt Repaid | -- | -100.00% | -233.77% | -- | -- |
| Issuance of Common Stock | -- | 1,052.56% | -- | -- | 483.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -7.20% | 100.00% | -96.85% |
| Cash from Financing | -- | -4.48% | -102.36% | 185.34% | 608.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -126.37% | 36,058.33% | -8,500.82% | -10,962.50% | 818,175.00% |